{"id":7172,"date":"2024-05-03T08:00:00","date_gmt":"2024-05-03T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/"},"modified":"2024-05-03T08:00:00","modified_gmt":"2024-05-03T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-mars-2024","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>F\u00f6rberedelser f\u00f6r start av klinisk studie med NEX-22 p\u00e5g\u00e5r och samarbetet med Novo Nordisk utvecklas v\u00e4l<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet 2024<\/p>\n<ul>\n<li>Inga v\u00e4sentliga h\u00e4ndelser under kvartalet.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Nanexa meddelade att i den p\u00e5g\u00e5ende granskningsprocessen av den kliniska pr\u00f6vningsans\u00f6kan f\u00f6r fas I-studien med NEX-22 har ytterligare kompletteringar efterfr\u00e5gats fr\u00e5n tyska l\u00e4kemedelsmyndigheten, vilket i den nya europeiska regulatoriska processen tar mer tid \u00e4n f\u00f6rv\u00e4ntat. Bolaget bed\u00f6mer att man kan erh\u00e5lla godk\u00e4nnande och komma ig\u00e5ng med studien mot slutet av andra kvartalet 2024.<\/li>\n<\/ul>\n<p>Finansiell \u00f6versikt<\/p>\n<p>1 januari &#8211; 31 mars 2024<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 7 754 (8 173) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -3 363 (-8 703) kSEK<\/li>\n<li>Periodens resultat uppgick till: -2 823 (-8 603) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,02 (-0,14) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -17 328 (-20 682) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 47 839 (60 500) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p>Rapportkommentar 3 maj kl 12:00<\/p>\n<p>En lives\u00e4nd kommentar med vd David Westberg h\u00e5lls den 3 maj kl 12:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig via <a href=\"https:\/\/www.youtube.com\/watch?v=vz8ItwILMtI\" rel=\"noopener\" target=\"_blank\">denna l\u00e4nk<\/a>.<\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2024-05-03 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/0a6e8a7e-2ee2-4a4b-b04b-87b677797d3a\/nanexa-delarsrapport-jan-mar-2024.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Jan Mar 2024<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f6rberedelser f\u00f6r start av klinisk studie med NEX-22 p\u00e5g\u00e5r och samarbetet med Novo Nordisk utvecklas v\u00e4l<\/p>\n","protected":false},"template":"","class_list":["post-7172","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q1_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"F\u00f6rberedelser f\u00f6r start av klinisk studie med NEX-22 p\u00e5g\u00e5r och samarbetet med Novo Nordisk utvecklas v\u00e4l\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-05-03T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB","og_description":"F\u00f6rberedelser f\u00f6r start av klinisk studie med NEX-22 p\u00e5g\u00e5r och samarbetet med Novo Nordisk utvecklas v\u00e4l","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-05-03T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2024"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}